About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Hematology
›
top-articles
Department of Hematology
39
(top 2%)
papers
354
(top 2%)
citations
9
(top 2%)
h
-index
18
(top 2%)
g
-index
44
all documents
410
doc citations
213
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Genetic Features of Late Onset Primary Hemophagocytic Lymphohistiocytosis in Adolescence or Adulthood
PLoS ONE
2014
65
2
Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma
Oncogene
2020
38
3
Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
Nature Communications
2021
37
4
A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
American Journal of Hematology
2014
36
5
<p>Progress in the identification of gene mutations involved in multiple myeloma</p>
OncoTargets and Therapy
2019
26
6
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study
Cancer Chemotherapy and Pharmacology
2017
25
7
Requirement for etoposide in the treatment of pregnancy related hemophagocytic lymphohistiocytosis: a multicenter retrospective study
Orphanet Journal of Rare Diseases
2019
20
8
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Chinese Journal of Cancer
2016
19
9
Myelomatous pleural effusion involvement in 23 patients with multiple myeloma: A single‐center clinical analysis
Thoracic Cancer
2015
18
10
Autologous stem cell transplant can overcome poor prognosis in patients with multiple myeloma with extramedullary plasmacytoma
Leukemia and Lymphoma
2014
11
11
Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation
Annals of Hematology
2019
10
12
What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
Frontiers in Oncology
2020
10
13
Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels
Oncology Letters
2017
9
14
Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma
International Journal of Hematology
2017
8
15
A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma
American Journal of Clinical Oncology: Cancer Clinical Trials
2018
8
16
Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
BioMed Research International
2018
7
17
<p>Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients</p>
OncoTargets and Therapy
2019
7
18
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
BMC Medicine
2022
7
19
Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma
Oncology Letters
2015
6
20
Fat fraction quantification of lumbar spine: comparison of T1-weighted two-point Dixon and single-voxel magnetic resonance spectroscopy in diagnosis of multiple myeloma
Diagnostic and Interventional Radiology
2020
6
21
Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing
Frontiers in Genetics
2021
6
22
Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma
BMC Medical Genomics
2019
5
23
Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells
Hematological Oncology
2022
4
24
Significance of p85 expression as a prognostic factor for patients with breast cancer
Oncology Letters
2014
3
25
Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
Experimental Hematology and Oncology
2023
3
26
Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B
Chinese Medical Journal
2016
2
27
Autoantibodies against β1-adrenergic receptor: response to induction therapy with bortezomib-containing regimens for multiple myeloma patients
Leukemia and Lymphoma
2018
2
28
Clinical Characteristics and Risk Factors for Pleural Effusion in Patients with Multiple Myeloma
International Journal of General Medicine
2021
2
29
Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor
Clinical Medicine Insights: Oncology
2022
2
30
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
Cancer Medicine
0
2
31
Simultaneous occurrence of splenic diffuse large B cell lymphoma and gastrointestinal stromal tumor in the stomach: a case report
Diagnostic Pathology
2018
1
32
Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China
Cancer Biology and Medicine
2021
1
33
Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study
Chinese Medical Journal
2021
1
34
Detection of Circulating Plasma Cells in Multiple Myeloma with Extramedullary Plasmacytoma
Blood
2015
1
35
Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Advances in Therapy
2022
1
36
Chemotherapy with the use of next‐generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
Cancer
2023
1
37
T cell receptor rearrangements in a patient with γ-heavy chain disease: A case report
Oncology Letters
2016
0
38
In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model
Clinical and Experimental Medicine
2022
0
39
Paraplegia secondary to disseminated mucormycosis: case report and literature review
BMC Infectious Diseases
2022
0
40
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
BMC Cancer
2022
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.